Title : Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy.

Pub. Date : 2013 Aug 1

PMID : 23744837






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Progesterone, an agonist for the progesterone receptor (PR), can be an efficacious and well-tolerated treatment in endometrial cancer. Progesterone progesterone receptor Mus musculus
2 Progesterone, an agonist for the progesterone receptor (PR), can be an efficacious and well-tolerated treatment in endometrial cancer. Progesterone progesterone receptor Mus musculus
3 Stromal deletion of PR as a single genetic change in these tumors induced progesterone resistance indicating that paracrine signaling through the stroma is essential for the progesterone therapeutic effects. Progesterone progesterone receptor Mus musculus
4 Stromal deletion of PR as a single genetic change in these tumors induced progesterone resistance indicating that paracrine signaling through the stroma is essential for the progesterone therapeutic effects. Progesterone progesterone receptor Mus musculus
5 Add-back of stromal PR expressed from a constitutively active promoter sensitized these tumors to progesterone therapy. Progesterone progesterone receptor Mus musculus
6 Our findings suggest that epigenetic derepression of stromal PR could be a potential therapeutic target for sensitizing hormone-refractory endometrial tumors to progesterone therapy. Progesterone progesterone receptor Mus musculus